SOLICITATION NOTICE
Q -- Metabolomic analysis assays
- Notice Date
- 3/26/2012
- Notice Type
- Presolicitation
- NAICS
- 621511
— Medical Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-120049-MD
- Archive Date
- 4/24/2012
- Point of Contact
- Miguel Diaz, Phone: (301) 402-4509, Caren N Rasmussen, Phone: (301) 402-4509
- E-Mail Address
-
miguel.diaz@nih.gov, cr214i@nih.gov
(miguel.diaz@nih.gov, cr214i@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Boulevard, EPS Suite 600, Room 6079, Rockville, MD 20852, UNITED STATES. Description The National Cancer Institute (NCI), Division of Cancer Control and Population Sciences (DCCPS) plans to procure on a sole source basis with Metabolon Inc of 617 Davis Drive Suite 400 Morrisville, NC 27560 to provide Metabolomic analysis assays. This acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1). The North American Industry Classification System Code is 621511 and the business size standard is $13.5 Million. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. The period of performance shall be twelve (12) months from date of award. Esophageal cancer consists of two main histological types: esophageal adenocarcinoma (EAC) and esophageal squamous cell carcinoma (ESCC). Although both diseases arise from the same organ, differences in incidence trends and risk factors indicate that they are etiologically distinct. The reasons for such a large variation in risk factors and disease incidence by histological type remain unclear. This suggests a need to identify biomarkers that may serve as a link to understanding the mechanisms through which established risk factors affect risk of EAC and ESCC. Recently, advances in the development of metabolite profiling technologies, or metabolomics, have emerged as a way to comprehensively study metabolism, metabolites and other small molecules in tissues and body fluids. The potential utility of metabolomics to cancer research has resulted in several studies of various malignancies. Although metabolomics holds much promise as a biomarker discovery method, a practical obstruction to its widespread adoption is that metabolomics labs typically provide only raw mass-spectrometry data rather translate the data into metabolites and metabolite concentrations. In practice, knowing that a mass spectrometry ‘peak' is elevated in response to a specific exposure, such as dietary components, is of little use to clinicians, and public health researchers. Specialized knowledge is required to render such information meaningful. In contrast, knowing that a specific metabolite responds to a specific exposure is of potentially great utility and general applicability. Metabolon Inc. provides broad linkage of MS peaks to actual metabolite identities across the metabolome (400+ metabolite identities). Metabolon Inc. utilizes specific informatics methods used to link mass-spectrometry output to actual metabolite identities. Furthermore, the DCCPS study will be conducted in concert with a number of other ongoing metabolomics projects that are slated to be done at Metabolon Inc. In order for study results to be comparable with those of the other projects and allow for pooling of the results from control subjects across these studies, the same laboratory must perform the analyses. For the aforementioned reasons, Metabolon Inc. is the only known lab that NCI can use to achieve its primary study aims. This is not a solicitation for competitive quotations. However, if any interested party believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI Office of Acquisitions on or before 11:00 AM EST on April 09, 2012. No electronic capability statements will be accepted (i.e. email or fax); an original and one copy must be sent to the NCI Office of Acquisitions to the address stated above. All questions must be in writing and can be faxed (301) 402-4513 or emailed to Miguel Diaz, Contract Specialist at miguel.diaz@nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov. No collect calls will be accepted. Please reference solicitation number NCI-120049-MD on all correspondences.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-120049-MD/listing.html)
- Record
- SN02705255-W 20120328/120326234319-34368e834253bcf75055987aa53dfd65 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |